Treatment News : Costs Spike for 2nd- and 3rd-Line ARVs and Late Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 19, 2013

Costs Spike for 2nd- and 3rd-Line ARVs and Late Treatment

The cost to treat HIV-positive people with second- and third-line antiretrovirals (ARVs) jumps by a respective 24 and 41 percent compared with first-line therapies, reports the National AIDS Treatment Advocacy Project (NATAP). Treatment for those who enter treatment with CD4s below 100 is also nearly twice as expensive as for those beginning treatment with CD4s above 350.

Reporting their findings at the 53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, researchers analyzed data from two cohorts selected from the MarketScan Commercial Claims and Encounters Database, which covered a span from 2007 to 2011, and from the MarketScan Lab Database, including data from 2007 to 2010. The first group followed 9,931 participants as they progressed from first- to third-line therapy. The second group included 486 participants on ARVs who provided data on CD4 counts, for a total of 1,503 tests.

After adjusting for such factors as an AIDS diagnosis, sex, age, region of the country and type of health insurance, the researchers found that the average cost per year to treat people with HIV (including all care, not just the cost of medications) amounted to $28,861 for those taking first-line therapy, $35,805 for second-line and $40,804 for third-line.

After adjusting for the same variables, the researchers found that the average cost to treat someone who began treatment with more than 350 CD4 cells was $2,526 per month. For those who began treatment with between 100 and 350 CD4s, the monthly cost was $2,378, and if CD4s were less than 100 the price jumped 92 percent, to $4,860.

To read the NATAP story, click here.

Search: HIV, antiretrovirals, ARVs, National AIDS Treatment Advocacy Project, first-line, second-line, third-line, therapy, CD4, 53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, MarketScan, NATAP

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.